anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As a pattern recognition receptor, Toll-like receptor 4 (TLR4) is crucial for the development and progression of acute kidney injury (AKI). This study aims to explore whether the deubiquitinase Usp9x influences the TLR4/NF-B pathway to cause sepsis-induced acute kidney injury (S-AKI). The model of AKI was established in Sprague-Dawley rats using the cecal ligation and puncture (CLP) method, while renal tubular epithelial cell NRK-52E was stimulated with lipopolysaccharide (LPS) in vitro. All plasmids were transfected into NRK-52E cells according to the indicated group. The deubiquitinase of TLR4 was predicted by the online prediction software Ubibrowser. Subsequently, Western blot and Pearson correlation analysis identified Usp9x protein as a potential candidate. Co-IP analysis verified the interaction between TLR4 and Usp9x. Further research revealed that overexpression of Usp9x inhibited degradation of TLR4 protein by downregulating its ubiquitination modification levels. Both in vivo and in vitro experiments observed that interference with Usp9x effectively alleviated the inflammatory response and apoptosis of renal tubular epithelial cells (RTECs) induced by CLP or LPS, whereas overexpression of TLR4 reversed this situation. Transfection with sh-Usp9x in NRK-52E cells suppressed the expression of proteins associated with the TLR4/NF-κB pathway induced by LPS. Moreover, the overexpression of TLR4 reversed the effect of sh-Usp9x transfection. Therefore, the deubiquitinase Usp9x interacts with TLR4, leading to the upregulation of its expression through deubiquitination modification, and the activation of the TLR4/NF-κB signaling pathway, thereby promoting inflammation and apoptosis in renal tubular epithelial cells and contributing to sepsis-induced acute kidney injury.
AVANDAMET was not studied in patients previously treated with metformin monotherapy; however, the combination of rosiglitazone and metformin was compared to rosiglitazone and metformin monotherapies in clinical trials. Bioequivalence between AVANDAMET and coadministered rosiglitazone tablets and metformin tablets has been demonstrated [see Clinical Pharmacology (12.3)]. 

A total of 670 patients with type 2 diabetes participated in two 26-week, randomized, double-blind, placebo/active-controlled trials designed to assess the efficacy of rosiglitazone in combination with metformin. Rosiglitazone, administered in either once-daily or twice-daily dosing regimens, was added to the therapy of patients who were inadequately controlled on 2.5 grams/day of metformin.

In one trial, patients inadequately controlled on 2.5 grams/day of metformin (mean baseline FPG 216 mg/dL and mean baseline HbA1c 8.8%) were randomized to receive rosiglitazone 4 mg once daily, rosiglitazone 8 mg once daily, or placebo in addition to metformin. A statistically significant improvement in FPG and HbA1c was observed in patients treated with the combinations of metformin and rosiglitazone 4 mg once daily and rosiglitazone 8 mg once daily, versus patients continued on metformin alone (see Table 11).

aP <0.0001 compared to metformin.

In a second 26-week trial, patients with type 2 diabetes inadequately controlled on 2.5 grams/day of metformin who were randomized to receive the combination of rosiglitazone 4 mg twice daily and metformin (N = 105) showed a statistically significant improvement in glycemic control with a mean treatment effect for FPG of -56 mg/dL and a mean treatment effect for HbA1c of -0.8% over metformin alone. The combination of metformin and rosiglitazone resulted in lower levels of FPG and HbA1c than either agent alone.
Patients in the interventional group will receive early antiplatelet treatment with oral aspirin within 3 hours of initiating intravenous thrombolysis. In addition, the best medical management will be administered according to the guidelines.
Acute myocardial infarction (AMI) has become a public health disease threatening public life safety due to its high mortality. The lateral-flow assay (LFA) of a typical cardiac biomarker, troponin I (cTnI), is essential for the timely warnings of AMI. However, it is a challenge to achieve an ultra-fast and highly-sensitive assay for cTnI (hs-cTnI) using current LFA, due to the limited performance of chromatographic membranes. Here, we propose a barbed arrow-like structure membrane (BAS Mem), which enables the unidirectional, fast flow and low-residual of liquid. The liquid is rectified through the forces generated by the sidewalls of the barbed arrow-like grooves. The rectification coefficient of liquid flow on BAS Mem is 14.5 (highest to date). Using BAS Mem to replace the conventional chromatographic membrane, we prepare batches of lateral-flow strips and achieve LFA of cTnI within 240 s, with a limit of detection of 1.97 ng mL-1. The lateral-flow strips exhibit a specificity of 100%, a sensitivity of 93.3% in detecting 25 samples of suspected AMI patients. The lateral-flow strips show great performance in providing reliable results for clinical diagnosis, with the potential to provide early warnings for AMI.
Green tea polyphenols (GTP) have been shown to ameliorate lipid metabolic disorders by regulating intestinal bacteria. Given the significant role of intestinal bacteriophages in shaping the gut microbiota, this study investigates GTP's influence on gut bacteriophage-bacteria interactions and lipid metabolism using metagenomics and metabonomics. The research results indicated that GTP significantly reduced body weight, serum triglycerides, leptin, insulin resistance, interleukin-6, and TNF-α levels while increasing adiponectin in ob/ob mice fed high-fat diet, aiding intestinal repair. GTP improved gut health by decreasing Enterobacter, Siphoviridae and Enterobacteria_phage_sfv, increasing Bifidobacterium and intestinal metabolites SCFA and hippuric acid. Correlation analysis showed negative correlations between Enterobacter sp. 50,588,862 and Enterobacteria_phages, Shigella_phages with 4-hydroxyphenylpyruvate and hippuric acid. Bifidobacterium choerinum and Bifidobacterium sp. AGR2158 were positively correlated with fatty acids and bile acids. In conclusion, GTP reduced fat accumulation and inflammation, enhanced gut barrier function in obese mice, closely associated with changes in the gut bacteriophage community.
OBJECTIVES: I. Determine whether glutamine is effective in reducing the acute treatment related diarrhea in patients receiving pelvic external beam radiation therapy as adjuvant or primary treatment of malignancy. II. Determine whether glutamine can reduce chronic treatment related enteropathy following completion of therapy. III. Determine whether glutamine causes any toxicity in this situation. IV. Provide initial reliability and validity data for a patient bowel function questionnaire.

OUTLINE: This is a randomized, double-blind, placebo controlled study. Patients are stratified by history of anterior resection of the rectum (yes vs no); total planned cumulative dose, including boost fields of external beam radiotherapy (4500-5350 cGy vs 5350-6000 cGy vs greater than 6000 cGy); use of fluorouracil (none vs bolus vs continuous infusion); and primary site (rectal cancer vs prostate cancer vs gynecological cancer vs other). Beginning the first or second day of radiotherapy, patients receive either oral glutamine or a placebo twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
The invention discloses a traditional Chinese medicine external application agent for treating osteoproliferation. According to traditional Chinese medicines, osteoproliferation is affected with wind, cold, dampness, heat and strain so as to cause hyperplasia change of neck, lumbar vertebra and knee joint, so that the nerve root is pressed, main and collateral channels are closed, qi and blood circulation is not smooth, and qi and blood are stagnated. The traditional Chinese medicine external application agent selects traditional Chinese medicines such as pyrola, holly leaf, caraway, fern palm flower, narrow-leaved lindernia, root of common sage herb, stylophorum lasiocarpum, gynura segetum, silkworm, sinew of deer, tiger osseocolla, and sheep marrow, which have effects of promoting blood circulation to remove blood stasis, expelling wind and removing cold and humidity, tonifying kidney, and strengthening tendons and bones. The traditional Chinese medicines are grinded into fine powder and then packaged. The agent is used for external application. Clinical tests of the institute prove that the total effective rate achieves 97.7%, so that the traditional Chinese medicine external application agent is worthy of clinical popularization and application.
Participants enrolled in this group will receive education concerning primary and secondary PROTECT DC goals. Primary PROTECT DC goals adhere to the following medication directives: 1) Anti-hypertensive, 2) Lipid Lowering, 3) Anti-Coagulant, and 4) Anti-Diabetic. PROTECT DC secondary goals include the following behaviors 1) Smoking Cessation, 2) Consuming an AHA Diet, 3) Regular Exercise, and 4) Knowledge of Stroke Risk and Warning Signs. Participants will also receive assistance with overcoming resource-related barriers to the PROTECT DC goals.
The present invention provides antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibody binds human MSR1 with high affinity. In certain embodiments, the antibody binds to MSR1 without blocking or blocking less than 90% of the binding of modified LDL to MSR 1. In some embodiments, the antibody binds to cell surface expressed MSR1 and internalizes. The antibodies of the invention may be fully human antibodies. The invention includes an anti-MSR 1 antibody or antigen-binding fragment thereof conjugated to a drug or therapeutic compound.
Abdominal aortic aneurysms (AAAs) expose patients to death caused by aortic rupture. Although screening of AAAs has been shown to decrease AAA-related mortality, translation into medical practice of screening is limited because there is no specific treatment to limit growth of AAAs below diameter thresholds for open surgery or stent graft. We have developed different approaches aimed at inducing healing and thereby stabilizing formed AAAs in animal models. We have identified TGF-beat1 as an inducer of experimental AAA healing. Cyclosporine A is an inducer of tumor growth factor - beta1 (TGF-beta1) in experimental AAAs and in human atherosclerotic AAAs in vitro, causing overgrowth of inflamed tissues. Since AAAs are caused by aortic wall atrophy, we have hypothesised and confirmed in animals, that cyclosporine AAA, when administrated during a short period of time, durably stabilizes small AAA diameter in animals, while inducing aortic wall reconstruction and healing.

The clinical trial ACA4 is a multicentric randomized, placebo controlled, double blind trial that will enrol 360 patients with small AAAs in France. Two doses of cyclosporine A will be tested against a placebo (three arms). Drug administration will be short, and AAA diameter evaluation will be performed for 2 years, by CT-scanner (main outcome) with no contrast, and duplex-scanner.
The present invention relates to a composition for preventing or treating diabetes-related diseases containing a Symplocos chinensis sp. plant extract or a compound isolated from the same as an active component. The Symplocos chinensis sp. plant extract or the compound isolated from the same promotes sugar absorption in adipocytes and has an effect of improving glucose tolerance and insulin resistance. Therefore, the Symplocos chinensis sp. plant extract or the compound isolated from the same is expected to be used in the development of a therapeutic agent for obesity, diabetes, metabolic syndrome, diabetes complications, etc., and health functional food and a composition for animal feed for alleviating obesity, diabetes, metabolic syndrome, diabetes complications, etc.
Pharmacodynamics of Hydrocortisone Butyrate Lotion is unknown.

Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression

Eighty-four (84) pediatric subjects (3 months to less than 18 years of age) with moderate to severe atopic dermatitis affecting at least 25% of body surface area (BSA) treated with Hydrocortisone Butyrate Lotion three times daily for up to 4 weeks were assessed for HPA axis suppression. The disease severity (moderate to severe atopic dermatitis) and the dosing regimen (three times daily) in this HPA axis trial were different from the subject population (mild to moderate atopic dermatitis) and the dosing regimen (twice daily) for which Hydrocortisone Butyrate Lotion is indicated. Seven of the 82 evaluable subjects (8.5%) demonstrated laboratory evidence of HPA axis suppression, where the criterion for defining HPA axis suppression was a serum cortisol level of less than or equal to 18 mcg/dL after cosyntropin stimulation. Subjects with HPA axis suppression ranged from 1 to 12 years of age and, at the time of enrollment, had 35% to 90% BSA involvement. These subjects did not develop any other signs or symptoms of HPA axis suppression. At the first follow-up visit, approximately 1 month after the conclusion of treatment, cosyntropin stimulation results of all subjects had returned to normal, with the exception of one subject. This last subject recovered adrenal function by the second post-treatment visit, 55 days post-treatment [see Warnings and Precautions (5.1),Use in Specific Populations (8.4)].
The safety and effectiveness of amoxicillin for the treatment of upper respiratory tract infections, and infections of the genitourinary tract, skin and skin structure and lower respiratory tract have been established in pediatric patients.  


The safety and effectiveness of amoxicillin for the treatment of H.Pylori infection have not been established in pediatric patients.  


Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. Dosing of amoxicillin should be modified in pediatric patients 12 weeks or younger (3 months or younger) [see Dosage and Administration (Error! Hyperlink reference not valid.)].
The ultimate objective of this study is to rationalize treatment decisions. It is our hope that this pilot study will provide the basis for further randomized prospective studies. The expected benefit is that the current treatment and outcome of pediatric parapneumonic effusions will be determined. Insights into the therapy that results in the least morbidity, hospital days, (and therefore cost) will be elucidated. If our hypothesis is valid, then a more aggressive surgical approach to the treatment of a parapneumonic effusion may be warranted. If the hypothesis is not valid, then the appropriate treatment for a parapneumonic effusion, irrespective of institution and personal opinion, should become more apparent.
The present invention discloses a medical composition with antiphlogosis, which is used for treating diseases, such as sore throat, diarrhea, dysentery, etc. The present invention particularly relates to a medical composition oral preparation which is prepared by using two kinds of traditional Chinese medicine of barberry, baical skullcap root, etc. as raw materials. The present invention aims at complementing the shortages of the existing oral medical preparations for treating the sore throat, the diarrhea, the dysentery, the chronic dysentery, etc., and providing shuanghuang inflammation relief drop pills of medical composition oral preparations having the advantages of high biological availability, rapid medicine absorption, rapid effect performance, low price and no pollution in the process of production. The shuanghuang inflammation relief drop pills related by the present invention use two kinds of traditional Chinese medicine of the barberry, the baical skullcap root, etc. as the raw materials which are matched with medicinal carriers used as substrates to prepare the shuanghuang inflammation relief drop pills.
Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
The present disclosure provides engineered  Vibrio sp . organisms. The organisms can be engineered to have an altered Chromosome II so that the altered Chromosome II can be used in  Vibrio sp . and other organisms for the cloning or amplification of nucleic acid molecules and for the expression and production of proteins and peptides in a  Vibrio sp . organism. One or more genetic elements have been deleted from Chromosome II and/or relocated from Chromosome II to Chromosome I. The engineered  Vibrio sp . organisms of the invention can also have signal sequences fused to proteins or peptides to be secreted from the cell. In some embodiments the engineered  Vibrio sp . organisms can have sequences that enable them to retain viability after incubation at low temperatures.
Only adult participants living in the community are included in the local evaluation. Three research questions are examined in detail by the local evaluation. First, what recruitment strategies are most effective in the rural service area of Real Relationships? The answers to this research question will increase the CAS's and the funder's understanding of recruitment in rural areas. Secondly, what are barriers to Real Relationships class/workshop attendance for adults who enrolled but did not participate in any workshops? Again, answers to this research question will increase CAS's and the funder's understanding of barriers to retention (from the point of entry into the program to when participation begins), particularly in rural areas. A better understanding of barriers at this point of the enrollment process can be used to develop programming that helps to avoid these barriers, and the development of programming aimed at reaching populations that have been missed due to specific barriers. Third, how do short- and long-term outcomes for participants who complete their Real Relationships class/workshop differ by the format of the class/workshop format (i.e., weekend workshop, multi-week classes)? The answers to this research question will increase CAS's and the funder's understanding of programming in this field by adding to the knowledge base regarding the most effective formats for achieving the outcomes relevant to the goals of Real Relationships. Results will also speak to the importance of other activities, such as case management and parenting classes, for achieving desired outcomes.
A 72 year-old male patient with a history of a hepatic cyst presented to our hospital with epigastric pain. The cyst had enlarged to approximately 130 mm and was diagnosed as a symptomatic hepatic cyst. Percutaneous cyst drainage was deemed challenging because of the risk of intestinal perforation; therefore, transgastric endoscopic ultrasound-guided hepatic cyst drainage was performed with external nasal cyst drainage. After cyst shrinkage was confirmed, minocycline hydrochloride was injected into the cyst through the nasal drainage tube, and the nasal cyst drainage was removed. Nine months after treatment, the cyst diameter markedly reduced to 12 mm on computed tomography, and the symptoms improved. In cases where surgery is complex or it is difficult to secure a percutaneous puncture line, endoscopic ultrasound-guided drainage and minocycline hydrochloride injection may be effective if a puncture route can be secured under endoscopic ultrasound.
Reiki has an essential place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, and is safe, effective, and economical. In the Reiki method, the energy is transferred through the hands, and a care provider nurse is a tool that performs their profession by touching in patient care and also shares the universal life energy, transferring the flowing and formed energy. When the literature is reviewed, there are a limited number of studies in which Reiki affects heart rate, cortisol level, and vital signs. However, there are not enough studies examining the effects of heart patients' symptoms, anxiety, and their condition on Reiki results. In this context, this study aimed to investigate the effects of Reiki energy on heart rhythm, biochemistry, cortisol findings, and anxiety in people with arrhythmia.

The study was conducted as a pretest-posttest, randomized prospective, single-blind and placebo-controlled. The study was conducted with patients who applied to a training and research hospital with arrhythmia complaints between April 5 and June 30, 2022. The data was collected using "Personal Information Form (PIF)" and "Beck Anxiety Scale (BAS)". Also, biochemical tests and cortisol findings and ECG (Electrocardiography) analyses were assessed.

PIF and BAS were applied to patients who agreed to participate in the study and met the inclusion criteria. Then blood was drawn for biochemical tests and cortisol findings and EKG was taken. Patients were randomized 1:1 into groups by a single therapist at a single institution according to a parallel design. There were three treatment arms in the study: Reiki treatment (n=22), Sham Reiki treatment (placebo)(n=22), and a control group with no treatment (n=22). A second-degree Reiki practitioner applied Reiki to the energy centers for 30 minutes in the Reiki group. On the second day, distant Reiki was also conducted for 30 minutes. The Sham Reiki group, on the other hand, was handled similarly to the Reiki practice by a student who had not been trained in Reiki. In the control group, nothing was done. One week later, BAS was applied to all patients, blood was drawn for biochemical testing and an ECG was recorded.
PURPOSE:To obtain a highly stable dentifrice free from volatilization of the fragrant ingredients and viscosity variation by simultaneously mixing an abrasive agent, caking agent, wetting agent and water followed, by defoaming under reduced pressures and then addition of an fragrance. CONSTITUTION:Firstly, the following agents are mixed simultaneously: (1) an abrasive agent (e.g. calcium secondary phosphate), (2) a caking agent (e.g. carboxymethylcellulose), (3) a wetting agent (e.g. glycerin) and (4) water. Second, the resulting mixture is defoamed under a reduced pressure of 10-300mmHg or so. Then, a fragrant component (e.g. peppermint oil, lemon oil) is added to the mixture, thus obtaining the objective dentifrice. With the above-process, ill-balancing for flavor due to partly volatilizing the fragrant ingredients can be prevented; that is, flavor can be highlighted through preventing the spoilage of fragrant ingredient composition along with entraining no air bubbles, thus obtaining the objective high-quality dentifrice also good in stability.